OVID THERAPEUTICS INC (OVID) Fundamental Analysis & Valuation

NASDAQ:OVID • US6904691010

Current stock price

2.66 USD
-0.19 (-6.67%)
At close:
2.72 USD
+0.06 (+2.26%)
After Hours:

This OVID fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. OVID Profitability Analysis

1.1 Basic Checks

  • In the past year OVID has reported negative net income.
  • In the past year OVID has reported a negative cash flow from operations.
  • OVID had negative earnings in 4 of the past 5 years.
  • In the past 5 years OVID reported 4 times negative operating cash flow.
OVID Yearly Net Income VS EBIT VS OCF VS FCFOVID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

1.2 Ratios

  • OVID's Return On Assets of -11.54% is amongst the best of the industry. OVID outperforms 80.62% of its industry peers.
  • OVID's Return On Equity of -13.33% is amongst the best of the industry. OVID outperforms 85.08% of its industry peers.
Industry RankSector Rank
ROA -11.54%
ROE -13.33%
ROIC N/A
ROA(3y)-25.52%
ROA(5y)-9.97%
ROE(3y)-37.23%
ROE(5y)-17.2%
ROIC(3y)N/A
ROIC(5y)N/A
OVID Yearly ROA, ROE, ROICOVID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for OVID so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OVID Yearly Profit, Operating, Gross MarginsOVID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. OVID Health Analysis

2.1 Basic Checks

  • OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OVID has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for OVID has been increased compared to 5 years ago.
  • There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OVID Yearly Shares OutstandingOVID Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
OVID Yearly Total Debt VS Total AssetsOVID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • OVID has an Altman-Z score of 9.40. This indicates that OVID is financially healthy and has little risk of bankruptcy at the moment.
  • OVID's Altman-Z score of 9.40 is amongst the best of the industry. OVID outperforms 80.43% of its industry peers.
  • OVID has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.4
ROIC/WACCN/A
WACC9.55%
OVID Yearly LT Debt VS Equity VS FCFOVID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 8.97 indicates that OVID has no problem at all paying its short term obligations.
  • OVID has a Current ratio of 8.97. This is in the better half of the industry: OVID outperforms 75.58% of its industry peers.
  • OVID has a Quick Ratio of 8.97. This indicates that OVID is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of OVID (8.97) is better than 75.58% of its industry peers.
Industry RankSector Rank
Current Ratio 8.97
Quick Ratio 8.97
OVID Yearly Current Assets VS Current LiabilitesOVID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. OVID Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 18.42% over the past year.
  • The Revenue has grown by 1181.27% in the past year. This is a very strong growth!
  • OVID shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.46% yearly.
EPS 1Y (TTM)18.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%146.15%
Revenue 1Y (TTM)1181.27%
Revenue growth 3Y69.09%
Revenue growth 5Y-10.46%
Sales Q2Q%844.74%

3.2 Future

  • OVID is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.80% yearly.
  • The Revenue is expected to grow by 56.48% on average over the next years. This is a very strong growth
EPS Next Y-70.18%
EPS Next 2Y-44.14%
EPS Next 3Y-35.28%
EPS Next 5Y-9.8%
Revenue Next Year-96.54%
Revenue Next 2Y-79.67%
Revenue Next 3Y-66.99%
Revenue Next 5Y56.48%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OVID Yearly Revenue VS EstimatesOVID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
OVID Yearly EPS VS EstimatesOVID Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. OVID Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OVID. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OVID. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OVID Price Earnings VS Forward Price EarningsOVID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OVID Per share dataOVID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

  • A cheap valuation may be justified as OVID's earnings are expected to decrease with -35.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-44.14%
EPS Next 3Y-35.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OVID Dividend Analysis

5.1 Amount

  • OVID does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OVID Fundamentals: All Metrics, Ratios and Statistics

OVID THERAPEUTICS INC

NASDAQ:OVID (4/22/2026, 8:00:02 PM)

After market: 2.72 +0.06 (+2.26%)

2.66

-0.19 (-6.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18
Earnings (Next)05-13
Inst Owners41%
Inst Owner Change0.02%
Ins Owners2.71%
Ins Owner Change1.79%
Market Cap401.74M
Revenue(TTM)7.25M
Net Income(TTM)-17.41M
Analysts87.06
Price Target4.81 (80.83%)
Short Float %6.76%
Short Ratio2.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)69.12%
Min EPS beat(2)-11.2%
Max EPS beat(2)149.43%
EPS beat(4)2
Avg EPS beat(4)50.35%
Min EPS beat(4)-11.2%
Max EPS beat(4)149.43%
EPS beat(8)6
Avg EPS beat(8)50.62%
EPS beat(12)8
Avg EPS beat(12)7.74%
EPS beat(16)11
Avg EPS beat(16)8.59%
Revenue beat(2)1
Avg Revenue beat(2)2589.6%
Min Revenue beat(2)-1.54%
Max Revenue beat(2)5180.73%
Revenue beat(4)3
Avg Revenue beat(4)3313.55%
Min Revenue beat(4)-1.54%
Max Revenue beat(4)7920.11%
Revenue beat(8)6
Avg Revenue beat(8)1696.06%
Revenue beat(12)10
Avg Revenue beat(12)1177.5%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.84%
PT rev (3m)12.84%
EPS NQ rev (1m)-1.07%
EPS NQ rev (3m)-1.07%
EPS NY rev (1m)-13.29%
EPS NY rev (3m)-13.29%
Revenue NQ rev (1m)-70.45%
Revenue NQ rev (3m)-70.45%
Revenue NY rev (1m)35.37%
Revenue NY rev (3m)35.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 55.4
P/FCF N/A
P/OCF N/A
P/B 3.07
P/tB 3.07
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.05
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -11.54%
ROE -13.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.52%
ROA(5y)-9.97%
ROE(3y)-37.23%
ROE(5y)-17.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.97
Quick Ratio 8.97
Altman-Z 9.4
F-Score5
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)11.63%
Cap/Depr(5y)82.98%
Cap/Sales(3y)21.18%
Cap/Sales(5y)31.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%146.15%
EPS Next Y-70.18%
EPS Next 2Y-44.14%
EPS Next 3Y-35.28%
EPS Next 5Y-9.8%
Revenue 1Y (TTM)1181.27%
Revenue growth 3Y69.09%
Revenue growth 5Y-10.46%
Sales Q2Q%844.74%
Revenue Next Year-96.54%
Revenue Next 2Y-79.67%
Revenue Next 3Y-66.99%
Revenue Next 5Y56.48%
EBIT growth 1Y31.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.49%
OCF growth 3YN/A
OCF growth 5YN/A

OVID THERAPEUTICS INC / OVID Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for OVID THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to OVID.


What is the valuation status of OVID THERAPEUTICS INC (OVID) stock?

ChartMill assigns a valuation rating of 0 / 10 to OVID THERAPEUTICS INC (OVID). This can be considered as Overvalued.


How profitable is OVID THERAPEUTICS INC (OVID) stock?

OVID THERAPEUTICS INC (OVID) has a profitability rating of 2 / 10.


What is the earnings growth outlook for OVID THERAPEUTICS INC?

The Earnings per Share (EPS) of OVID THERAPEUTICS INC (OVID) is expected to decline by -70.18% in the next year.